Catalyst Pharmaceuticals (CPRX) EBIT (2010 - 2026)

Catalyst Pharmaceuticals' EBIT history runs 17 years deep, the most recent figure standing at $73.2 million for Q1 2026.

• Quarterly EBIT rose 15.57% year-over-year to $73.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $267.6 million (up 15.68% YoY) and the FY2025 annual result came in at $257.8 million, up 32.11% from the prior year.
• EBIT was $73.2 million for Q1 2026 at Catalyst Pharmaceuticals, up from $61.8 million in the prior quarter.
• Across five years, EBIT topped out at $73.2 million in Q1 2026 and bottomed at -$37.2 million in Q3 2023.
• A 5-year average of $42.0 million and a median of $46.7 million in 2023 frame the typical range for EBIT.
• Annual changes were most pronounced in 2023 — EBIT sank 248.15% — and 2024, when it jumped 236.9%.
• Catalyst Pharmaceuticals' EBIT stood at $30.8 million in 2022, then jumped by 35.36% to $41.7 million in 2023, then surged by 50.73% to $62.8 million in 2024, then slipped by 1.59% to $61.8 million in 2025, then rose by 18.41% to $73.2 million in 2026.
• Business Quant data shows CPRX's EBIT at $73.2 million in Q1 2026, $61.8 million in Q4 2025, and $66.3 million in Q3 2025.